🧾 What This Document Is

This is a 6-K filing, which is a report foreign companies (like French-based Inventiva) submit to the SEC to announce major news. This specific filing contains a press release. Think of it as an official, legally required announcement to investors about a significant company update.

🏢 What The Company Does

👉 Inventiva is a biotech company working on a pill for a serious liver disease called MASH. MASH (metabolic dysfunction-associated steatohepatitis) is a severe, progressive liver disease with few treatments. Their lead drug candidate is lanifibranor, an oral pill they are testing in a final-stage (Phase 3) clinical trial. They are listed on stock exchanges in Paris and on the NASDAQ in the U.S.

🚀 Key Moves: A Leadership Overhaul

The company is bringing in three high-profile executives to strengthen its team. This isn't just a hiring spree; it's a strategic build-out for the next critical phase.

• Axel-Sven Malkomes (new CFO): 🏦 He has over 30 years in finance and investment banking. Most recently, he was the CFO at CureVac, an mRNA company, where he played a key role in its acquisition by BioNTech. His experience includes preparing companies for public listings and navigating M&A.
• Susan Coles (new Chief Legal Officer): ⚖️ She has deep life sciences legal experience, including serving as Inventiva's own General Counsel in the past (2012-2014 & 2019-2021), during which time the company listed on the NASDAQ. She knows the company and the regulatory landscape intimately.
• Pamela Herbster (new Chief People Officer): 👥 She is an HR leader from big pharma, having worked at Sage Therapeutics (overseen by Supernus Pharma), Merck KGaA, and Biogen. Her role is to build the culture and organizational strength needed for a company potentially on the verge of launching a product.

👉 Why it matters: The company is intentionally adding senior leaders with specific expertise in finance, legal governance, and organizational scaling. This signals they are transitioning from a pure research company to a commercial-ready organization.

⏰ The Catalyst: Phase 3 Data Readout

The hires are directly tied to a massive upcoming milestone. Inventiva expects the top-line results from its NATiV3 Phase 3 trial for lanifibranor in the fourth quarter of 2026.

• This data will be a make-or-break moment. Positive results could lead to regulatory submissions and set the stage for the drug's first commercial sale.
• The CEO, Andrew Obenshain, explicitly states this "defines a moment" for Inventiva and that the new team is in place to guide the company from data readout to potential commercialization.

👥 Transition of Founding Team

The new hires replace two long-serving executives, but they are not leaving entirely.

• Jean Volatier (original CFO) will move to EVP Finance & Corporate Social Responsibility.
• Nathalie Harroy (original Head of HR) will also remain with the company in a supporting role.
• 👉 Why it matters: This is a graceful transition, not a hostile clean-out. It brings fresh, external experience while retaining deep institutional knowledge from the founders, which is crucial during a high-stakes period.

🔮 What's Next: The Path to Commercialization

The filing makes the company's path very clear: survive and succeed the Q4 2026 Phase 3 data readout. If the data is positive, the newly built leadership team is expected to execute a plan for:

1. Regulatory submissions (seeking approval to sell the drug).
2. Potential commercialization (launching the product).
3. Managing the company's growth as it potentially transforms from a R&D-focused to a commercial-stage business.

⚖️ Big Picture

👍 Strengths: A clear, high-stakes catalyst (Phase 3 data). A leadership team with proven experience in deals, public markets, and scaling biotechs. A graceful succession plan that preserves company history.

⚠️ Risks: The entire strategy hinges on the Q4 2026 trial data. If the trial fails, the commercialization plans become irrelevant. The company is also spending significant money on leadership and trials, making cash runway a key metric to watch.

🧠 The Analogy

Imagine Inventiva as a rock band that's spent years writing and perfecting a single, powerful album (lanifibranor). The Phase 3 data is their make-or-break album release show. Before the curtain goes up, they've just hired a world-class tour manager (CFO), a veteran entertainment lawyer (CLO), and a top-notch crew chief (CPO) to make sure the show goes off flawlessly and they're ready for the world tour (commercial launch) that might follow.

🧩 Final Takeaway

Inventiva is strategically retooling its leadership ahead of a make-or-break drug trial result. This hiring surge is a strong signal that management is preparing the company not just to report data, but to act on it and transition into a commercial entity. The clock is now ticking toward Q4 2026.